Is Kamada (KMDA) a Strong Growth Investment? Here Are 3 Reasons to Agree.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 06 2025
0mins
Should l Buy KMDA?
Source: NASDAQ.COM
Growth Stock Investment: Investors are increasingly looking for growth stocks that promise above-average returns, but identifying these stocks can be challenging due to their inherent risks and volatility.
Kamada's Growth Potential: Kamada (KMDA) is highlighted as a strong growth stock, boasting a projected EPS growth of 57.3% this year and an efficient asset utilization ratio of 0.46, outperforming the industry average.
Positive Earnings Trends: The upward trend in Kamada's earnings estimates, with a 4.4% increase over the past month, contributes to its favorable Zacks Rank of #2, indicating strong buy potential.
Investment Recommendations: Zacks Investment Research suggests that Kamada's combination of growth metrics and positive earnings revisions positions it well for future outperformance, making it an attractive option for growth investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KMDA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KMDA
Wall Street analysts forecast KMDA stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 8.980
Low
13.00
Averages
14.00
High
15.00
Current: 8.980
Low
13.00
Averages
14.00
High
15.00
About KMDA
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Kamada to Announce Q4 Earnings on March 11
- Earnings Announcement: Kamada is set to release its Q4 earnings on March 11 before market open, with a consensus EPS estimate of $0.08, reflecting a 14.3% year-over-year increase, indicating ongoing improvements in profitability that may attract investor interest.
- Revenue Expectations: Analysts forecast Kamada's Q4 revenue to reach $46.62 million, representing a 19.5% year-over-year growth, which underscores the company's strong performance in market demand and product sales, potentially laying the groundwork for future expansion.
- Historical Performance: Over the past two years, Kamada has beaten EPS estimates 63% of the time and revenue estimates 63% of the time, suggesting a consistent ability to exceed market expectations, which may bolster confidence in its future performance.
- Future Outlook: Kamada anticipates achieving double-digit profitable growth by 2026, a projection that not only reflects the company's confidence in future market opportunities but also may attract long-term investors, further driving stock price appreciation.
See More
Kamada Q4 Earnings Miss Expectations
- Earnings Performance: Kamada reported Q4 GAAP EPS of $0.06, missing expectations by $0.02, indicating pressure on profitability that may affect investor confidence moving forward.
- Revenue Growth Lags: The Q4 revenue of $44.68 million, while up 14.6% year-over-year, fell short of expectations by $1.94 million, reflecting unmet market demand that could impact future strategic decisions.
- 2026 Performance Outlook: Kamada affirms its 2026 revenue guidance of $200 million to $205 million, which is close to the $204.97 million consensus but only represents a 13% growth, highlighting challenges in achieving robust growth.
- Adjusted EBITDA Guidance: The company anticipates adjusted EBITDA between $50 million and $53 million for 2026, representing a 23% increase compared to 2025 results, although market confidence in its profitability may be affected.
See More
Analyst Predicts Increase in Hubspot Stock, Along with Insights on McGraw Hill, UHS, and Other Stocks.
Report Overview: Recent reports from investment and research firms provide insights into analysts' perspectives on various companies.
Disclaimer: The views expressed in these reports do not reflect the opinions or recommendations of Barron’s.
Investment Services: Some report issuers may have existing or potential investment-banking relationships with the companies analyzed.
Purpose of Reports: The reports serve as a sampling of analyst thinking rather than definitive investment advice.
See More
Kamada Forecasts $200M-$205M Revenue for 2026 with 13% Growth
- 2026 Financial Outlook: Kamada projects revenues of $200 million to $205 million for 2026, representing a 13% year-over-year increase based on the midpoint of 2025 guidance, highlighting the company's ongoing organic growth potential across its diverse product portfolio in the biopharmaceutical sector.
- Adjusted EBITDA Growth: The company anticipates adjusted EBITDA to reach $50 million to $53 million in 2026, reflecting a 23% increase from the midpoint of 2025, which signifies a substantial enhancement in profitability and boosts investor confidence.
- Strong Cash Position: Kamada expects to end 2025 with approximately $75 million in cash, ensuring financial flexibility for future investments and business expansions, thereby strengthening its competitive edge in global markets.
- Strategic Development Focus: The company will continue to prioritize new business development and M&A transactions to accelerate long-term profitable growth, a strategy that will enrich its marketed product portfolio and generate synergies with existing operations.
See More
Kamada Secures Supply Tender Extension, Ensuring $5-$7 Million Annual Sales
- Contract Extension: Kamada has been awarded an extension of its existing supply tender from Canadian Blood Services for four specialty plasma-derived products, ensuring annual sales of approximately $5-$7 million between Q2-26 and Q1-28, thereby securing its market position in Canada.
- Revenue Guidance Reaffirmed: The company reiterated its full-year 2025 revenue guidance of $178 million to $182 million and adjusted EBITDA of $40 million to $44 million, reflecting strong and consistent performance in the market.
- Growth Outlook: Kamada projects double-digit growth in revenues and profitability in 2026, driven by its robust commercial portfolio and expansion of its biosimilar offerings, indicating strong competitive positioning in future markets.
- Strategic Development: The company intends to pursue additional contracts in key strategic territories, leveraging its strong cash position and existing commercial infrastructure to drive long-term growth and enhance its international market presence.
See More
Kamada Secures Supply Tender Extension from CBS, Ensuring $5-$7 Million Annual Sales
- Contract Extension: Kamada has secured an extension of its existing supply tender from Canadian Blood Services, ensuring annual sales of approximately $5-$7 million between Q2-26 and Q1-28, thereby reinforcing its leadership position in the Canadian market.
- Revenue Guidance Reaffirmed: The company reiterated its full-year 2025 revenue guidance of $178 million to $182 million and adjusted EBITDA guidance of $40 million to $44 million, reflecting strong confidence in future performance.
- Growth Outlook: Kamada projects double-digit growth in revenues and profitability in 2026, driven by a robust commercial portfolio and expansion of its biosimilar offerings, indicating significant commercial potential in international markets.
- Strategic Development: The company plans to enhance revenue growth through the expansion of normal source plasma sales and collection operations, showcasing its long-term growth strategy in the biopharmaceutical sector.
See More
Kamada to Announce Q4 Earnings on March 11
- Earnings Announcement: Kamada is set to release its Q4 earnings on March 11 before market open, with a consensus EPS estimate of $0.08, reflecting a 14.3% year-over-year increase, indicating ongoing improvements in profitability that may attract investor interest.
- Revenue Expectations: Analysts forecast Kamada's Q4 revenue to reach $46.62 million, representing a 19.5% year-over-year growth, which underscores the company's strong performance in market demand and product sales, potentially laying the groundwork for future expansion.
- Historical Performance: Over the past two years, Kamada has beaten EPS estimates 63% of the time and revenue estimates 63% of the time, suggesting a consistent ability to exceed market expectations, which may bolster confidence in its future performance.
- Future Outlook: Kamada anticipates achieving double-digit profitable growth by 2026, a projection that not only reflects the company's confidence in future market opportunities but also may attract long-term investors, further driving stock price appreciation.
See More
Kamada Q4 Earnings Miss Expectations
- Earnings Performance: Kamada reported Q4 GAAP EPS of $0.06, missing expectations by $0.02, indicating pressure on profitability that may affect investor confidence moving forward.
- Revenue Growth Lags: The Q4 revenue of $44.68 million, while up 14.6% year-over-year, fell short of expectations by $1.94 million, reflecting unmet market demand that could impact future strategic decisions.
- 2026 Performance Outlook: Kamada affirms its 2026 revenue guidance of $200 million to $205 million, which is close to the $204.97 million consensus but only represents a 13% growth, highlighting challenges in achieving robust growth.
- Adjusted EBITDA Guidance: The company anticipates adjusted EBITDA between $50 million and $53 million for 2026, representing a 23% increase compared to 2025 results, although market confidence in its profitability may be affected.
See More
Analyst Predicts Increase in Hubspot Stock, Along with Insights on McGraw Hill, UHS, and Other Stocks.
Report Overview: Recent reports from investment and research firms provide insights into analysts' perspectives on various companies.
Disclaimer: The views expressed in these reports do not reflect the opinions or recommendations of Barron’s.
Investment Services: Some report issuers may have existing or potential investment-banking relationships with the companies analyzed.
Purpose of Reports: The reports serve as a sampling of analyst thinking rather than definitive investment advice.
See More
Kamada Forecasts $200M-$205M Revenue for 2026 with 13% Growth
- 2026 Financial Outlook: Kamada projects revenues of $200 million to $205 million for 2026, representing a 13% year-over-year increase based on the midpoint of 2025 guidance, highlighting the company's ongoing organic growth potential across its diverse product portfolio in the biopharmaceutical sector.
- Adjusted EBITDA Growth: The company anticipates adjusted EBITDA to reach $50 million to $53 million in 2026, reflecting a 23% increase from the midpoint of 2025, which signifies a substantial enhancement in profitability and boosts investor confidence.
- Strong Cash Position: Kamada expects to end 2025 with approximately $75 million in cash, ensuring financial flexibility for future investments and business expansions, thereby strengthening its competitive edge in global markets.
- Strategic Development Focus: The company will continue to prioritize new business development and M&A transactions to accelerate long-term profitable growth, a strategy that will enrich its marketed product portfolio and generate synergies with existing operations.
See More
Kamada Secures Supply Tender Extension, Ensuring $5-$7 Million Annual Sales
- Contract Extension: Kamada has been awarded an extension of its existing supply tender from Canadian Blood Services for four specialty plasma-derived products, ensuring annual sales of approximately $5-$7 million between Q2-26 and Q1-28, thereby securing its market position in Canada.
- Revenue Guidance Reaffirmed: The company reiterated its full-year 2025 revenue guidance of $178 million to $182 million and adjusted EBITDA of $40 million to $44 million, reflecting strong and consistent performance in the market.
- Growth Outlook: Kamada projects double-digit growth in revenues and profitability in 2026, driven by its robust commercial portfolio and expansion of its biosimilar offerings, indicating strong competitive positioning in future markets.
- Strategic Development: The company intends to pursue additional contracts in key strategic territories, leveraging its strong cash position and existing commercial infrastructure to drive long-term growth and enhance its international market presence.
See More
Kamada Secures Supply Tender Extension from CBS, Ensuring $5-$7 Million Annual Sales
- Contract Extension: Kamada has secured an extension of its existing supply tender from Canadian Blood Services, ensuring annual sales of approximately $5-$7 million between Q2-26 and Q1-28, thereby reinforcing its leadership position in the Canadian market.
- Revenue Guidance Reaffirmed: The company reiterated its full-year 2025 revenue guidance of $178 million to $182 million and adjusted EBITDA guidance of $40 million to $44 million, reflecting strong confidence in future performance.
- Growth Outlook: Kamada projects double-digit growth in revenues and profitability in 2026, driven by a robust commercial portfolio and expansion of its biosimilar offerings, indicating significant commercial potential in international markets.
- Strategic Development: The company plans to enhance revenue growth through the expansion of normal source plasma sales and collection operations, showcasing its long-term growth strategy in the biopharmaceutical sector.
See More
